Correlated Drug Terms (2)

---

	Name (Synonyms)	Correlation
drug254	ArtemiC Wiki	1.00
drug2122	Placebo Wiki	0.05

Correlated MeSH Terms (4)

---

	Name (Synonyms)	Correlation
D003141	Communicable Diseases NIH	0.08
D007239	Infection NIH	0.05
D045169	Severe Acute Respiratory Syndrome NIH	0.05
D018352	Coronavirus Infections NIH	0.04

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: Assess reduction of inflammation in COVID-19 patients, potentially leading to a decrease in the need for critical care. This will be assessed by measurement of C-reactive protein levels before and after the intervention. Units: mg/dL

Measure: C-reactive protein

Time: Baseline through post-treatment (6 days)

---

Other Outcomes

Description: Comparison of mortality between intervention and control groups

Measure: Death within 30 Days

Time: Baseline through 30 days

---

Description: Comparison of days spend in ICU between intervention and control groups

Measure: ICU-free days at 30 days

Time: Baseline through 30 days

---

Description: Comparison of days spent in hospital between intervention and control groups

Measure: Hospital length of stay

Time: From date of hospital admission through date of discharge or death, whichever comes first (up to 100 days)

---

Description: Comparison of mechanical ventilation incidence between intervention and control groups

Measure: Need for invasive mechanical ventilation

Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)

---

Description: Comparison of mean biomarker level change between intervention and control groups. Units: pg/mL

Measure: Biomarker levels (interleukin-6)

Time: Baseline through post-treatment (6 days)

---

Description: Comparison of mean biomarker level change between intervention and control groups. Units: ug/mL

Measure: Biomarker levels (d-dimer)

Time: Baseline through post-treatment (6 days)

---

Description: Comparison of mean biomarker level change between intervention and control groups. Units: u/L

Measure: Biomarker levels (lactate dehydrogenase)

Time: Baseline through post-treatment (6 days)

---

Description: Comparison of ECMO incidence between intervention and control groups

Measure: Need for ECMO

Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)

---

Description: Compare frequency of major adverse cardiac events (MACE) between intervention and control groups

Measure: Major adverse cardiac events

Time: From date of enrollment through date of discharge or death, whichever comes first (up to 100 days)

---

Description: Comparison of PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaire results on a computer-adaptive platform between intervention and control groups using T-scores. Scale mean = 50, standard deviation = 10.

Measure: Patient-reported functional status

Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)

---

Description: Patients will be administered a 20-question self-report measure of PTSD symptoms. Total scores range from 0-80. Scores of 31-33 or above generally indicate clinically likely PTSD.

Measure: PTSD Checklist

Time: Administered at 1, 3, 6, and 12 months post discharge (1 year)

---